Kolkata : Novo Nordisk, a global healthcare company,
today announced the launch of Ozempic®
(injectable semaglutide) in India. Ozempic® is a once-weekly GLP-1 RA
(receptor agonist) indicated as an adjunct to diet and exercise for adults
living with uncontrolled type 2 diabetes
mellitus (T2DM).
The
arrival of Ozempic® in India comes at a crucial time. According to the World
Health Organisation’s 2023-24 estimates, India has 101 million (roughly 11.4 %
of India’s population) people living with diabetes, making it the second
largest diabetes-affected populations in the world after China. The country
also has 136 million individuals with prediabetes and 254 million people living
with generalised obesity, signalling an accelerating health challenge that
requires effective, evidence-based therapies.
Clinical benefits of
Ozempic®:
·
Demonstrated
powerful HbA1c reduction with compelling weight-loss benefits, supporting
better metabolic health.
·
Suitable
for adults with HbA1c ≥=7%, including those with high cardiovascular risk or
established cardiovascular disease.
·
Provides
additional lowering of cardiovascular events, a key concern for people with
long-standing T2DM.
·
Offers
protection against chronic kidney disease progression, supporting long-term
health outcomes.
“Bringing
Ozempic® to India is a major milestone” said Vikrant Shrotriya - Managing Director, Novo Nordisk India. “Backed
by global trust, proven clinical excellence & world class quality,
reinforced by a robust supply chain, Ozempic® offers Indian doctors an
effective treatment choice. Our goal is to provide patients an innovative &
accessible therapy that offers improved glycaemic control, meaningful weight
management and long-term heart and kidney protection – all delivered through a
simple, easy-to-use pen device. This once-weekly treatment demonstrates Novo
Nordisk’s ongoing commitment to better health outcomes and chronic disease
care.”
How does Ozempic® work?
Ozempic®
is a GLP-1 receptor agonist that helps:
·
Improve
glycaemic control and reduce HbA1c.
·
Regulate
appetite and food intake by acting on areas of the brain that control hunger.
·
Support
weight loss in people with T2DM.
·
Reduce
risks of cardiovascular and kidney complications associated with diabetes.
Its
once-weekly administration and globally trusted safety profile make it a
preferred treatment option in clinical practice across several countries.
Ozempic®,
the original GLP-1 RA (semaglutide) therapy, has been researched and developed
by Novo Nordisk for over 20 years and is backed by over 38 million
patient-years of global clinical use. Semaglutide was recently included in
WHO’s Model List of Essential Medicines - highlighting the proven health
benefits of this innovative treatment for people living with diabetes and
obesity.
Ozempic®
is now available in India as 0.25 mg, 0.5 mg and 1 mg in FlexTouch®Pen - an
easy-to-use, once-weekly pen device. The multiple dosing strengths support
physician-guided titration and long-term diabetes management.
No comments:
Post a Comment